S-1/A: Contineum Therapeutics Eyes Nasdaq Listing with $150 Million IPO

Contineum Therapeutics, a clinical-stage biopharmaceutical company, is seeking to raise approximately $150 million through an initial public offering to advance its pipeline of therapies for neuroscience, inflammation, and immunology indications.

Summary

• Contineum Therapeutics is a clinical-stage biopharmaceutical company planning an IPO to raise approximately $150 million.
• The company focuses on developing oral small molecule therapies for neuroscience, inflammation, and immunology (NI&I) indications.
• Their lead asset, PIPE-791, is being developed for idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (Progressive MS).
• PIPE-307, their second drug candidate, is being developed for depression and relapse remitting MS (RRMS) in collaboration with Johnson & Johnson (J&J).
• In January 2024, Contineum nominated CTX-343, a peripherally-restricted LPA1R antagonist, and commenced preclinical studies.
• The company intends to use the IPO proceeds to advance the development of PIPE-791, complete Phase 2 clinical trials of PIPE-307, and fund other research and development activities.
• Contineum estimates net proceeds from the offering to be approximately $136.6 million, or $157.5 million if underwriters exercise their option to purchase additional shares in full, assuming an initial public offering price of $17.00 per share.
• The company believes its existing cash, cash equivalents, and marketable securities, together with the estimated net proceeds from this offering, will be sufficient to fund its projected operations through at least the end of 2028.

Sentiment

Score: 7

Explanation: The document presents a balanced view, highlighting both the potential of the company's pipeline and the risks associated with drug development and commercialization. The partnership with J&J and the progress in clinical trials are positive indicators, while the need for additional funding and the competitive landscape are potential challenges.

Positives

• PIPE-791 has shown promising preclinical data and completed a Phase 1 clinical trial.
• PIPE-307 is partnered with Johnson & Johnson, providing financial and development support.
• The company has a strong team with expertise in small molecule drug design.
• The company is pursuing clinically validated targets and novel therapeutic approaches.
• The company has worldwide rights to its LPA1R programs and discovery portfolio.

Negatives

• The company has incurred significant operating expenses since inception and anticipates that its operating expenses will continue to significantly increase for the foreseeable future.
• The company has a limited operating history and the drug candidates it has developed are in the early stages of clinical development.
• The company is heavily dependent on the success of PIPE-791 and PIPE-307, both of which are in the early stages of clinical development.
• The company may not be successful in its efforts to identify and develop additional drug candidates or identify additional indications.
• The company has and may continue to conduct future clinical trials outside of the United States. The FDA and other regulatory authorities or ethics committees may not accept data from such trials, in which case the company's development plans will be delayed.

Risks

• Clinical drug development is a lengthy, expensive, and risky process with uncertain timelines and outcomes.
• Regulatory approval processes are unpredictable, lengthy, and time-consuming.
• The company may require significant additional capital to complete the development and commercialization of its drug candidates.
• The J&J License Agreement may not result in the successful development of PIPE-307.
• The company faces significant competition from biotechnology, pharmaceutical, and medical device companies.
• Even if PIPE-791 or PIPE-307 receives marketing approval, it may fail to achieve market acceptance.

Future Outlook

The company plans to advance its clinical programs, including PIPE-791 and PIPE-307, and to continue exploring new drug candidates. They anticipate significant increases in operating expenses for the foreseeable future.

Management Comments

• The company aims to significantly impact the clinical disability associated with NI&I diseases with small molecules designed to modulate innate pathways to restore function.

Industry Context

The biopharmaceutical industry is highly competitive, with numerous companies developing therapies for NI&I indications. Contineum faces competition from established pharmaceutical companies, specialty pharmaceutical companies, and other biotechnology companies.

Comparison to Industry Standards

• The document mentions approved therapies for IPF, such as pirfenidone (Esbriet by Genentech/Roche) and nintedanib (Ofev by Boehringer Ingelheim), highlighting the existing treatment landscape.
• It also references third-party LPA1R antagonist programs, such as those by Bristol-Myers Squibb and AbbVie, indicating the competitive landscape for this specific target.
• For RRMS, the document notes the existence of over 20 approved DMTs, but emphasizes the lack of therapies that directly promote remyelination, which is the goal of PIPE-307.
• The document cites the ReBuild trial with clemastine as clinical proof-of-concept for M1R antagonism and remyelination in RRMS, setting a benchmark for PIPE-307.

Related Party Transactions

• Series C Preferred Stock Financing: From February 2021 until August 2023, the company issued and sold an aggregate of 9,349,906 shares of its Series C preferred stock at a cash purchase price of $15.00 per share for an aggregate purchase price of approximately $140.2 million to entities affiliated with Baker Brothers, Versant Ventures, Sectoral Asset Management, and JJDC.
• J&J License Agreement: In February 2023, the company entered into the J&J License Agreement with J&J, pursuant to which the company granted J&J an exclusive, worldwide license to develop, manufacture and commercialize PIPE-307 in all indications. The company received an upfront payment of $50.0 million and is eligible to receive milestone payments and royalties. Separately, JJDC made a $25.0 million equity investment in the company.

Stakeholder Impact

• Shareholders: The IPO will provide liquidity and potential value appreciation for existing shareholders.
• Employees: The company's growth and success will depend on attracting, retaining, and motivating qualified personnel.
• Patients: The company's therapies aim to address unmet medical needs in NI&I indications, potentially improving patient outcomes.
• Collaborators: The company's partnerships, such as the one with J&J, are crucial for the development and commercialization of its drug candidates.

Next Steps

• Submit a CTA to the MHRA to commence a Phase 1b open-label trial of PIPE-791 to measure the relationship of PK to lung and brain receptor occupancy by PET imaging in 2024.
• Initiate a Phase 2 trial for PIPE-307 for the treatment of depression in 2024 (by J&J).
• Submit an IND to the FDA to support the planned Phase 2 trial in IPF in 2025 following completion of the planned six-month rodent and nine-month minipig GLP toxicity studies.
• Submit an IND to the FDA to support the planned Phase 2 trial in Progressive MS in 2025 following completion of the planned six-month rodent and nine-month minipig GLP toxicity studies for PIPE-791.
• Commence a proof-of-concept Phase 2 trial of PIPE-791 for Progressive MS in 2025.
• File an IND with the FDA for CTX-343 in 2025 and, pending authorization, plan to initiate a Phase 1 trial of CTX-343 in healthy volunteers that same year.

Key Dates

Keywords

Contineum Therapeutics, IPO, PIPE-791, PIPE-307, LPA1R antagonist, M1R inhibitor, biopharmaceutical, clinical stage, neurology, inflammation, immunology, CTX-343